索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的疗效解析

罗学宏，舒方国，王永亮

（陕西省西乡县人民医院外二科，陕西 汉中，723500）

浏览次数：175次 下载次数：336次

摘要：

目的 分析索利那新联合坦索罗辛治疗芋型前列腺炎的疗效。方法 从我院收治的患者中选取150例Ⅲ型前列腺炎患者，随机分为对照组和观察组，各75例。对照组患者予以坦索罗辛治疗，观察组予以索利那新联合坦索罗辛治疗，对比两组患者的治疗总有效率、不良反应发生率及治疗前后的心理状态。结果 观察组的治疗总有效率、不良反应发生率分别为 97.33%、4.00%，对照组的治疗总有效率和不良反应发生率分别为80.00%、16.00%，观察组的治疗总有效率高于对照组，不良反应率低于对照组（P<0.05）。治疗前，两组患者的SAS及SDS评分比较，差异无统计学意义（P>0.05）；治疗后，两组患者的SAS及SDS评分均得到显著改善，且观察组改善情况优于对照组（P<0.05）。结论 索利那新联合坦索罗辛治疗芋型前列腺炎的效果显著，安全性高，且可以有效改善患者的心理状态，值得临床广泛推广。

关键词：索利那新；坦索罗辛；Ⅲ型前列腺炎

中图分类号：R697.33文献标志码：A文章编号：2096-1413(2017)06-0066-02

Effect analysis of solifenacin combined with tamsulosin in the treatment

of type III prostatitis
LUO Xue-hong, SHU Fang-guo, WANG Yong-liang
(the Second Department of Surgery, People's Hospital of Xixiang County in Shaanxi Province, Hanzhong 723500, China)

ABSTRACT: Objective To analyze the clinical effect of solifenacin combined with tamsulos in the treatment of type III prostatitis. Methods One hundred and fifty cases of patients with type III prostatitis were selected, and were randomly divided into control group and observation group, with 75 cases in each group. The patients in the control group received tamsulosin, while the observation group accepted solifenacin combined with tamsulos. The total clinical effective rate, the incidence rate of adverse reactions and mental state before and after treatment of the two groups were compared. Results The total clinical effective rate and incidence rate of adverse reactions of the observation group were 97.33% , 4.00% respectively, while those of the control group were 80.00% , 16.00% respectively, the total clinical effective rate of observation group was higher than that of the control group, and the incidence rate of adverse reactions of the observation group was lower than that of the control group (P<0.05). Before treatment, there was no significant difference in SAS and SDS scores between the two groups (P>0.05). After treatment, the SAS and SDS scores of the two groups were better than those before treatment, and the SAS and SDS scores of the observation group were better than those of the control group (P<0.05). Conclusion Solifenacin combined with tamsulos in the treatment of type III prostatitis has significant clinical
effect and high safety, it can effectively improve the patients mental state, which is worthy of clinical popularization.

KEYWORDS: solifenacin; tamsulos; type III prostatitis

参考文献：
[1] 张昭宏.联用索利那新与坦索罗辛治疗Ⅲ型前列腺炎的效果探析 [J].当代医药论丛,2016,14(6):157-158.
[2] 南勇,毛琳琳,李苏,等.索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床价值分析[J].中国社区医师,2014,30(28):52.
[3] 范志华.索利那新联合坦索罗辛治疗芋型前列腺炎的临床效果分析[J].当代医学,2016,22(2):121-122.
[4] 桂金勇,童宏华,杨巧英,等.索利那新联合坦索罗辛治疗,Ⅲ型前列腺炎的临床效果分析[J].赣南医学院学报,2015,35(1):116-117.
[5] 尚辉.索利那新联合坦索罗辛治疗芋型前列腺炎的临床效果观察[J].中国现代药物应用,2016,10(11):135-136.
[6] 赵万辉,曹楚潇,却学云,等.索利那新联合坦索罗辛治疗44例芋型前列腺炎的临床效果[J].中国现代药物应用,2015,9(15):122-123.
[7] 郭建华,龚曼,胡巍,等.索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床研究[J].中华泌尿外科杂志,2013,34(11):839-842.
[8] 宋大龙,孙兆林,刘军,等.索利那新联合坦索罗辛治疗膀胱过度活动症的疗效研究[J].中华全科医学,2012,10(9):1358-1359.